共 151 条
[11]
Paton V(2021)Evolution of HER2-low expression from primary to recurrent breast cancer NPJ Breast Cancer 7 137-2795
[12]
Bajamonde A(2022)Evolution of low HER2 expression between early and advanced-stage breast cancer Eur J Cancer (Oxford, England: 1990) 163 35-145
[13]
Wolff AC(2010)American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784-4013
[14]
Hammond MEH(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118-1382
[15]
Allison KH(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-478
[16]
Harvey BE(2018)Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Arch Pathol Lab Med 142 1364-111
[17]
Mangu PB(2015)Breast cancer subtypes predispose the site of distant metastases Am J Clin Pathol 143 471-e133
[18]
Bartlett JMS(2018)Surviving at a distant site: The organotropism of metastatic breast cancer Semin Diagn Pathol 35 108-1161
[19]
Tarantino P(2022)Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression/gene amplification in breast cancer in the modern age: a single institution experience and pooled literature review study Clin Breast Cancer 22 e123-163
[20]
Hamilton E(2021)Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Lancet Oncol 22 1151-1183